Dental Patient Care America, Inc.
Dental Patient Care America, Inc. (DPAT) Stock Competitors & Peer Comparison
See (DPAT) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DPAT | $0.02 | +0.00% | 361.2K | -1.50 | -$0.01 | N/A |
| FSNUY | $12.42 | -0.60% | 111.8B | 22.56 | $0.55 | +2.22% |
| FSNUF | $46.21 | +0.00% | 26B | 21.10 | $2.19 | +2.28% |
| JDHIF | $6.27 | +0.00% | 20.1B | 34.84 | $0.18 | N/A |
| JDHIY | $5.10 | +0.00% | 16.3B | 28.33 | $0.18 | N/A |
| FMCQF | $52.15 | +0.00% | 15.3B | 21.03 | $2.48 | +3.13% |
| BDUUY | $32.33 | +0.00% | 12.8B | 28.36 | $1.14 | +2.79% |
| IHHHF | $1.19 | +0.00% | 10.5B | 17.00 | $0.07 | +4.88% |
| BDULF | $0.61 | +0.00% | 9.7B | 20.33 | $0.03 | +3.64% |
| BDUUF | $0.59 | +0.00% | 9.4B | 19.67 | $0.03 | +3.76% |
Stock Comparison
DPAT vs FSNUY Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, FSNUY has a market cap of 111.8B. Regarding current trading prices, DPAT is priced at $0.02, while FSNUY trades at $12.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas FSNUY's P/E ratio is 22.56. In terms of profitability, DPAT's ROE is +0.45%, compared to FSNUY's ROE of +0.02%. Regarding short-term risk, DPAT is more volatile compared to FSNUY. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check FSNUY's competition here
DPAT vs FSNUF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, FSNUF has a market cap of 26B. Regarding current trading prices, DPAT is priced at $0.02, while FSNUF trades at $46.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas FSNUF's P/E ratio is 21.10. In terms of profitability, DPAT's ROE is +0.45%, compared to FSNUF's ROE of +0.02%. Regarding short-term risk, DPAT is more volatile compared to FSNUF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check FSNUF's competition here
DPAT vs JDHIF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, JDHIF has a market cap of 20.1B. Regarding current trading prices, DPAT is priced at $0.02, while JDHIF trades at $6.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas JDHIF's P/E ratio is 34.84. In terms of profitability, DPAT's ROE is +0.45%, compared to JDHIF's ROE of +0.05%. Regarding short-term risk, DPAT is less volatile compared to JDHIF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check JDHIF's competition here
DPAT vs JDHIY Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, JDHIY has a market cap of 16.3B. Regarding current trading prices, DPAT is priced at $0.02, while JDHIY trades at $5.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas JDHIY's P/E ratio is 28.33. In terms of profitability, DPAT's ROE is +0.45%, compared to JDHIY's ROE of +0.05%. Regarding short-term risk, DPAT is more volatile compared to JDHIY. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check JDHIY's competition here
DPAT vs FMCQF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, FMCQF has a market cap of 15.3B. Regarding current trading prices, DPAT is priced at $0.02, while FMCQF trades at $52.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas FMCQF's P/E ratio is 21.03. In terms of profitability, DPAT's ROE is +0.45%, compared to FMCQF's ROE of +0.04%. Regarding short-term risk, DPAT is more volatile compared to FMCQF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check FMCQF's competition here
DPAT vs BDUUY Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, BDUUY has a market cap of 12.8B. Regarding current trading prices, DPAT is priced at $0.02, while BDUUY trades at $32.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas BDUUY's P/E ratio is 28.36. In terms of profitability, DPAT's ROE is +0.45%, compared to BDUUY's ROE of +0.16%. Regarding short-term risk, DPAT is more volatile compared to BDUUY. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check BDUUY's competition here
DPAT vs IHHHF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, IHHHF has a market cap of 10.5B. Regarding current trading prices, DPAT is priced at $0.02, while IHHHF trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas IHHHF's P/E ratio is 17.00. In terms of profitability, DPAT's ROE is +0.45%, compared to IHHHF's ROE of +0.08%. Regarding short-term risk, DPAT is more volatile compared to IHHHF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check IHHHF's competition here
DPAT vs BDULF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, BDULF has a market cap of 9.7B. Regarding current trading prices, DPAT is priced at $0.02, while BDULF trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas BDULF's P/E ratio is 20.33. In terms of profitability, DPAT's ROE is +0.45%, compared to BDULF's ROE of +0.16%. Regarding short-term risk, DPAT is more volatile compared to BDULF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check BDULF's competition here
DPAT vs BDUUF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, BDUUF has a market cap of 9.4B. Regarding current trading prices, DPAT is priced at $0.02, while BDUUF trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas BDUUF's P/E ratio is 19.67. In terms of profitability, DPAT's ROE is +0.45%, compared to BDUUF's ROE of +0.16%. Regarding short-term risk, DPAT is more volatile compared to BDUUF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check BDUUF's competition here
DPAT vs RMYHY Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, RMYHY has a market cap of 5.9B. Regarding current trading prices, DPAT is priced at $0.02, while RMYHY trades at $6.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas RMYHY's P/E ratio is 623.00. In terms of profitability, DPAT's ROE is +0.45%, compared to RMYHY's ROE of +0.18%. Regarding short-term risk, DPAT is more volatile compared to RMYHY. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check RMYHY's competition here
DPAT vs RMSYF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, RMSYF has a market cap of 5.9B. Regarding current trading prices, DPAT is priced at $0.02, while RMSYF trades at $25.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas RMSYF's P/E ratio is 510.20. In terms of profitability, DPAT's ROE is +0.45%, compared to RMSYF's ROE of +0.18%. Regarding short-term risk, DPAT is more volatile compared to RMSYF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check RMSYF's competition here
DPAT vs ANHGY Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, ANHGY has a market cap of 4B. Regarding current trading prices, DPAT is priced at $0.02, while ANHGY trades at $5.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas ANHGY's P/E ratio is 23.87. In terms of profitability, DPAT's ROE is +0.45%, compared to ANHGY's ROE of N/A. Regarding short-term risk, DPAT is more volatile compared to ANHGY. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check ANHGY's competition here
DPAT vs BUHPF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, BUHPF has a market cap of 3.4B. Regarding current trading prices, DPAT is priced at $0.02, while BUHPF trades at $4.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas BUHPF's P/E ratio is 17.96. In terms of profitability, DPAT's ROE is +0.45%, compared to BUHPF's ROE of +0.28%. Regarding short-term risk, DPAT is more volatile compared to BUHPF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check BUHPF's competition here
DPAT vs BUGDF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, BUGDF has a market cap of 3.4B. Regarding current trading prices, DPAT is priced at $0.02, while BUGDF trades at $4.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas BUGDF's P/E ratio is 15.67. In terms of profitability, DPAT's ROE is +0.45%, compared to BUGDF's ROE of +0.28%. Regarding short-term risk, DPAT is more volatile compared to BUGDF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check BUGDF's competition here
DPAT vs MCVEF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, MCVEF has a market cap of 3B. Regarding current trading prices, DPAT is priced at $0.02, while MCVEF trades at $19.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas MCVEF's P/E ratio is 82.63. In terms of profitability, DPAT's ROE is +0.45%, compared to MCVEF's ROE of +0.06%. Regarding short-term risk, DPAT is more volatile compared to MCVEF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check MCVEF's competition here
DPAT vs ORPEF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, ORPEF has a market cap of 2.3B. Regarding current trading prices, DPAT is priced at $0.02, while ORPEF trades at $14.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas ORPEF's P/E ratio is 0.03. In terms of profitability, DPAT's ROE is +0.45%, compared to ORPEF's ROE of -0.16%. Regarding short-term risk, DPAT is less volatile compared to ORPEF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check ORPEF's competition here
DPAT vs MCVEY Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, MCVEY has a market cap of 2.2B. Regarding current trading prices, DPAT is priced at $0.02, while MCVEY trades at $16.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas MCVEY's P/E ratio is 40.37. In terms of profitability, DPAT's ROE is +0.45%, compared to MCVEY's ROE of +0.06%. Regarding short-term risk, DPAT is more volatile compared to MCVEY. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check MCVEY's competition here
DPAT vs TTALF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, TTALF has a market cap of 1.6B. Regarding current trading prices, DPAT is priced at $0.02, while TTALF trades at $12.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas TTALF's P/E ratio is 19.33. In terms of profitability, DPAT's ROE is +0.45%, compared to TTALF's ROE of +0.15%. Regarding short-term risk, DPAT is more volatile compared to TTALF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check TTALF's competition here
DPAT vs RAFLF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, RAFLF has a market cap of 1.5B. Regarding current trading prices, DPAT is priced at $0.02, while RAFLF trades at $0.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas RAFLF's P/E ratio is 26.91. In terms of profitability, DPAT's ROE is +0.45%, compared to RAFLF's ROE of +0.04%. Regarding short-term risk, DPAT is more volatile compared to RAFLF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check RAFLF's competition here
DPAT vs RYHTY Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, RYHTY has a market cap of 1.4B. Regarding current trading prices, DPAT is priced at $0.02, while RYHTY trades at $7.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas RYHTY's P/E ratio is -3.83. In terms of profitability, DPAT's ROE is +0.45%, compared to RYHTY's ROE of -0.02%. Regarding short-term risk, DPAT is more volatile compared to RYHTY. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check RYHTY's competition here
DPAT vs LWSCF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, LWSCF has a market cap of 1.2B. Regarding current trading prices, DPAT is priced at $0.02, while LWSCF trades at $13.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas LWSCF's P/E ratio is 44.63. In terms of profitability, DPAT's ROE is +0.45%, compared to LWSCF's ROE of +0.07%. Regarding short-term risk, DPAT is more volatile compared to LWSCF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check LWSCF's competition here
DPAT vs RHCGF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, RHCGF has a market cap of 1.2B. Regarding current trading prices, DPAT is priced at $0.02, while RHCGF trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas RHCGF's P/E ratio is -3.27. In terms of profitability, DPAT's ROE is +0.45%, compared to RHCGF's ROE of -0.07%. Regarding short-term risk, DPAT is less volatile compared to RHCGF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check RHCGF's competition here
DPAT vs LTGHF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, LTGHF has a market cap of 1.1B. Regarding current trading prices, DPAT is priced at $0.02, while LTGHF trades at $0.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas LTGHF's P/E ratio is -19.69. In terms of profitability, DPAT's ROE is +0.45%, compared to LTGHF's ROE of +0.29%. Regarding short-term risk, DPAT is more volatile compared to LTGHF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check LTGHF's competition here
DPAT vs LTGHY Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, LTGHY has a market cap of 1.1B. Regarding current trading prices, DPAT is priced at $0.02, while LTGHY trades at $3.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas LTGHY's P/E ratio is -21.29. In terms of profitability, DPAT's ROE is +0.45%, compared to LTGHY's ROE of +0.40%. Regarding short-term risk, DPAT is more volatile compared to LTGHY. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check LTGHY's competition here
DPAT vs RHKJF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, RHKJF has a market cap of 1B. Regarding current trading prices, DPAT is priced at $0.02, while RHKJF trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas RHKJF's P/E ratio is 21.55. In terms of profitability, DPAT's ROE is +0.45%, compared to RHKJF's ROE of +0.03%. Regarding short-term risk, DPAT is less volatile compared to RHKJF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check RHKJF's competition here
DPAT vs RKAGY Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, RKAGY has a market cap of 986.7M. Regarding current trading prices, DPAT is priced at $0.02, while RKAGY trades at $7.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas RKAGY's P/E ratio is 21.06. In terms of profitability, DPAT's ROE is +0.45%, compared to RKAGY's ROE of +0.03%. Regarding short-term risk, DPAT is more volatile compared to RKAGY. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check RKAGY's competition here
DPAT vs NWKHY Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, NWKHY has a market cap of 950.7M. Regarding current trading prices, DPAT is priced at $0.02, while NWKHY trades at $7.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas NWKHY's P/E ratio is 11.47. In terms of profitability, DPAT's ROE is +0.45%, compared to NWKHY's ROE of +0.13%. Regarding short-term risk, DPAT is more volatile compared to NWKHY. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check NWKHY's competition here
DPAT vs WHTCF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, WHTCF has a market cap of 862.2M. Regarding current trading prices, DPAT is priced at $0.02, while WHTCF trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas WHTCF's P/E ratio is -42.57. In terms of profitability, DPAT's ROE is +0.45%, compared to WHTCF's ROE of -0.03%. Regarding short-term risk, DPAT is more volatile compared to WHTCF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check WHTCF's competition here
DPAT vs EXETF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, EXETF has a market cap of 764.3M. Regarding current trading prices, DPAT is priced at $0.02, while EXETF trades at $9.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas EXETF's P/E ratio is 14.25. In terms of profitability, DPAT's ROE is +0.45%, compared to EXETF's ROE of +0.66%. Regarding short-term risk, DPAT is more volatile compared to EXETF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check EXETF's competition here
DPAT vs JXFGF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, JXFGF has a market cap of 755.6M. Regarding current trading prices, DPAT is priced at $0.02, while JXFGF trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas JXFGF's P/E ratio is 14.00. In terms of profitability, DPAT's ROE is +0.45%, compared to JXFGF's ROE of +0.03%. Regarding short-term risk, DPAT is less volatile compared to JXFGF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check JXFGF's competition here
DPAT vs KDGTF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, KDGTF has a market cap of 675.1M. Regarding current trading prices, DPAT is priced at $0.02, while KDGTF trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas KDGTF's P/E ratio is -1.67. In terms of profitability, DPAT's ROE is +0.45%, compared to KDGTF's ROE of N/A. Regarding short-term risk, DPAT is more volatile compared to KDGTF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check KDGTF's competition here
DPAT vs WFHG Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, WFHG has a market cap of 470.6M. Regarding current trading prices, DPAT is priced at $0.02, while WFHG trades at $7.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas WFHG's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to WFHG's ROE of +0.22%. Regarding short-term risk, DPAT is more volatile compared to WFHG. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check WFHG's competition here
DPAT vs ORRRY Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, ORRRY has a market cap of 371.5M. Regarding current trading prices, DPAT is priced at $0.02, while ORRRY trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas ORRRY's P/E ratio is -0.33. In terms of profitability, DPAT's ROE is +0.45%, compared to ORRRY's ROE of +0.91%. Regarding short-term risk, DPAT is more volatile compared to ORRRY. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check ORRRY's competition here
DPAT vs BTMDW Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, BTMDW has a market cap of 292.9M. Regarding current trading prices, DPAT is priced at $0.02, while BTMDW trades at $1.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas BTMDW's P/E ratio is 0.05. In terms of profitability, DPAT's ROE is +0.45%, compared to BTMDW's ROE of -0.19%. Regarding short-term risk, DPAT is more volatile compared to BTMDW. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check BTMDW's competition here
DPAT vs MKLNF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, MKLNF has a market cap of 217.6M. Regarding current trading prices, DPAT is priced at $0.02, while MKLNF trades at $11.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas MKLNF's P/E ratio is 19.23. In terms of profitability, DPAT's ROE is +0.45%, compared to MKLNF's ROE of +0.14%. Regarding short-term risk, DPAT is more volatile compared to MKLNF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check MKLNF's competition here
DPAT vs MFCSF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, MFCSF has a market cap of 209.4M. Regarding current trading prices, DPAT is priced at $0.02, while MFCSF trades at $10.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas MFCSF's P/E ratio is 7.14. In terms of profitability, DPAT's ROE is +0.45%, compared to MFCSF's ROE of +0.84%. Regarding short-term risk, DPAT is more volatile compared to MFCSF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check MFCSF's competition here
DPAT vs CHHHF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, CHHHF has a market cap of 129.2M. Regarding current trading prices, DPAT is priced at $0.02, while CHHHF trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas CHHHF's P/E ratio is -51.25. In terms of profitability, DPAT's ROE is +0.45%, compared to CHHHF's ROE of -0.05%. Regarding short-term risk, DPAT is more volatile compared to CHHHF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check CHHHF's competition here
DPAT vs COLRF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, COLRF has a market cap of 125.5M. Regarding current trading prices, DPAT is priced at $0.02, while COLRF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas COLRF's P/E ratio is -8.00. In terms of profitability, DPAT's ROE is +0.45%, compared to COLRF's ROE of +0.02%. Regarding short-term risk, DPAT is less volatile compared to COLRF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check COLRF's competition here
DPAT vs VTIAF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, VTIAF has a market cap of 95.9M. Regarding current trading prices, DPAT is priced at $0.02, while VTIAF trades at $5.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas VTIAF's P/E ratio is -6.79. In terms of profitability, DPAT's ROE is +0.45%, compared to VTIAF's ROE of -0.63%. Regarding short-term risk, DPAT is more volatile compared to VTIAF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check VTIAF's competition here
DPAT vs MCIOF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, MCIOF has a market cap of 54M. Regarding current trading prices, DPAT is priced at $0.02, while MCIOF trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas MCIOF's P/E ratio is -1.22. In terms of profitability, DPAT's ROE is +0.45%, compared to MCIOF's ROE of N/A. Regarding short-term risk, DPAT is more volatile compared to MCIOF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check MCIOF's competition here
DPAT vs ASSF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, ASSF has a market cap of 45.3M. Regarding current trading prices, DPAT is priced at $0.02, while ASSF trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas ASSF's P/E ratio is -33.33. In terms of profitability, DPAT's ROE is +0.45%, compared to ASSF's ROE of -6.63%. Regarding short-term risk, DPAT is more volatile compared to ASSF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check ASSF's competition here
DPAT vs KONEF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, KONEF has a market cap of 44.3M. Regarding current trading prices, DPAT is priced at $0.02, while KONEF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas KONEF's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to KONEF's ROE of -6.56%. Regarding short-term risk, DPAT is less volatile compared to KONEF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check KONEF's competition here
DPAT vs USNU Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, USNU has a market cap of 22.2M. Regarding current trading prices, DPAT is priced at $0.02, while USNU trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas USNU's P/E ratio is -9.41. In terms of profitability, DPAT's ROE is +0.45%, compared to USNU's ROE of -0.62%. Regarding short-term risk, DPAT is more volatile compared to USNU. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check USNU's competition here
DPAT vs HQDA Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, HQDA has a market cap of 18.6M. Regarding current trading prices, DPAT is priced at $0.02, while HQDA trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas HQDA's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to HQDA's ROE of +0.00%. Regarding short-term risk, DPAT is more volatile compared to HQDA. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check HQDA's competition here
DPAT vs NVLPF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, NVLPF has a market cap of 17.3M. Regarding current trading prices, DPAT is priced at $0.02, while NVLPF trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas NVLPF's P/E ratio is 19.79. In terms of profitability, DPAT's ROE is +0.45%, compared to NVLPF's ROE of +0.05%. Regarding short-term risk, DPAT is more volatile compared to NVLPF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check NVLPF's competition here
DPAT vs EVGRF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, EVGRF has a market cap of 14.9M. Regarding current trading prices, DPAT is priced at $0.02, while EVGRF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas EVGRF's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to EVGRF's ROE of +0.67%. Regarding short-term risk, DPAT is less volatile compared to EVGRF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check EVGRF's competition here
DPAT vs FPCG Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, FPCG has a market cap of 10.3M. Regarding current trading prices, DPAT is priced at $0.02, while FPCG trades at $1,025.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas FPCG's P/E ratio is 0.09. In terms of profitability, DPAT's ROE is +0.45%, compared to FPCG's ROE of +0.00%. Regarding short-term risk, DPAT is more volatile compared to FPCG. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check FPCG's competition here
DPAT vs NUMIF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, NUMIF has a market cap of 8.8M. Regarding current trading prices, DPAT is priced at $0.02, while NUMIF trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas NUMIF's P/E ratio is -0.45. In terms of profitability, DPAT's ROE is +0.45%, compared to NUMIF's ROE of -1.95%. Regarding short-term risk, DPAT is less volatile compared to NUMIF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check NUMIF's competition here
DPAT vs HLYK Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, HLYK has a market cap of 7.8M. Regarding current trading prices, DPAT is priced at $0.02, while HLYK trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas HLYK's P/E ratio is -1.37. In terms of profitability, DPAT's ROE is +0.45%, compared to HLYK's ROE of +2.41%. Regarding short-term risk, DPAT is less volatile compared to HLYK. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check HLYK's competition here
DPAT vs RHEP Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, RHEP has a market cap of 7.5M. Regarding current trading prices, DPAT is priced at $0.02, while RHEP trades at $3.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas RHEP's P/E ratio is -1.56. In terms of profitability, DPAT's ROE is +0.45%, compared to RHEP's ROE of +1.29%. Regarding short-term risk, DPAT is more volatile compared to RHEP. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check RHEP's competition here
DPAT vs BICX Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, BICX has a market cap of 7.3M. Regarding current trading prices, DPAT is priced at $0.02, while BICX trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas BICX's P/E ratio is -1.05. In terms of profitability, DPAT's ROE is +0.45%, compared to BICX's ROE of +0.40%. Regarding short-term risk, DPAT is more volatile compared to BICX. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check BICX's competition here
DPAT vs XCRT Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, XCRT has a market cap of 7M. Regarding current trading prices, DPAT is priced at $0.02, while XCRT trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas XCRT's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to XCRT's ROE of +2.48%. Regarding short-term risk, DPAT is more volatile compared to XCRT. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check XCRT's competition here
DPAT vs VLXC Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, VLXC has a market cap of 6.8M. Regarding current trading prices, DPAT is priced at $0.02, while VLXC trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas VLXC's P/E ratio is -9.49. In terms of profitability, DPAT's ROE is +0.45%, compared to VLXC's ROE of +0.58%. Regarding short-term risk, DPAT is more volatile compared to VLXC. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check VLXC's competition here
DPAT vs GBCS Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, GBCS has a market cap of 6.6M. Regarding current trading prices, DPAT is priced at $0.02, while GBCS trades at $2.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas GBCS's P/E ratio is -3.16. In terms of profitability, DPAT's ROE is +0.45%, compared to GBCS's ROE of +0.56%. Regarding short-term risk, DPAT is more volatile compared to GBCS. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check GBCS's competition here
DPAT vs RVLWF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, RVLWF has a market cap of 5.3M. Regarding current trading prices, DPAT is priced at $0.02, while RVLWF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas RVLWF's P/E ratio is -0.30. In terms of profitability, DPAT's ROE is +0.45%, compared to RVLWF's ROE of +3.95%. Regarding short-term risk, DPAT is more volatile compared to RVLWF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check RVLWF's competition here
DPAT vs EPWCF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, EPWCF has a market cap of 2.5M. Regarding current trading prices, DPAT is priced at $0.02, while EPWCF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas EPWCF's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to EPWCF's ROE of +0.00%. Regarding short-term risk, DPAT is less volatile compared to EPWCF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check EPWCF's competition here
DPAT vs GRST Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, GRST has a market cap of 2.3M. Regarding current trading prices, DPAT is priced at $0.02, while GRST trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas GRST's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to GRST's ROE of +0.30%. Regarding short-term risk, DPAT is more volatile compared to GRST. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check GRST's competition here
DPAT vs TOKIF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, TOKIF has a market cap of 1.8M. Regarding current trading prices, DPAT is priced at $0.02, while TOKIF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas TOKIF's P/E ratio is -0.01. In terms of profitability, DPAT's ROE is +0.45%, compared to TOKIF's ROE of -0.83%. Regarding short-term risk, DPAT is more volatile compared to TOKIF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check TOKIF's competition here
DPAT vs SMAS Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, SMAS has a market cap of 1.5M. Regarding current trading prices, DPAT is priced at $0.02, while SMAS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas SMAS's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to SMAS's ROE of N/A. Regarding short-term risk, DPAT is more volatile compared to SMAS. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check SMAS's competition here
DPAT vs MDGP Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, MDGP has a market cap of 1.5M. Regarding current trading prices, DPAT is priced at $0.02, while MDGP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas MDGP's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to MDGP's ROE of -2.19%. Regarding short-term risk, DPAT is more volatile compared to MDGP. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check MDGP's competition here
DPAT vs NOVC Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, NOVC has a market cap of 1.2M. Regarding current trading prices, DPAT is priced at $0.02, while NOVC trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas NOVC's P/E ratio is -0.20. In terms of profitability, DPAT's ROE is +0.45%, compared to NOVC's ROE of +0.12%. Regarding short-term risk, DPAT is more volatile compared to NOVC. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check NOVC's competition here
DPAT vs JRSS Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, JRSS has a market cap of 1.1M. Regarding current trading prices, DPAT is priced at $0.02, while JRSS trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas JRSS's P/E ratio is -0.13. In terms of profitability, DPAT's ROE is +0.45%, compared to JRSS's ROE of +2.63%. Regarding short-term risk, DPAT is more volatile compared to JRSS. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check JRSS's competition here
DPAT vs PHMB Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, PHMB has a market cap of 1.1M. Regarding current trading prices, DPAT is priced at $0.02, while PHMB trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas PHMB's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to PHMB's ROE of N/A. Regarding short-term risk, DPAT is more volatile compared to PHMB. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check PHMB's competition here
DPAT vs GNOW Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, GNOW has a market cap of 859.7K. Regarding current trading prices, DPAT is priced at $0.02, while GNOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas GNOW's P/E ratio is -0.01. In terms of profitability, DPAT's ROE is +0.45%, compared to GNOW's ROE of +0.00%. Regarding short-term risk, DPAT is more volatile compared to GNOW. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check GNOW's competition here
DPAT vs ERUC Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, ERUC has a market cap of 638.1K. Regarding current trading prices, DPAT is priced at $0.02, while ERUC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas ERUC's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to ERUC's ROE of N/A. Regarding short-term risk, DPAT is more volatile compared to ERUC. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check ERUC's competition here
DPAT vs MSITF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, MSITF has a market cap of 480K. Regarding current trading prices, DPAT is priced at $0.02, while MSITF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas MSITF's P/E ratio is -0.10. In terms of profitability, DPAT's ROE is +0.45%, compared to MSITF's ROE of N/A. Regarding short-term risk, DPAT is less volatile compared to MSITF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check MSITF's competition here
DPAT vs NXGT Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, NXGT has a market cap of 369.9K. Regarding current trading prices, DPAT is priced at $0.02, while NXGT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas NXGT's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to NXGT's ROE of +0.09%. Regarding short-term risk, DPAT is more volatile compared to NXGT. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check NXGT's competition here
DPAT vs ARPC Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, ARPC has a market cap of 336.6K. Regarding current trading prices, DPAT is priced at $0.02, while ARPC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas ARPC's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to ARPC's ROE of -0.56%. Regarding short-term risk, DPAT is more volatile compared to ARPC. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check ARPC's competition here
DPAT vs JNHMF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, JNHMF has a market cap of 303.7K. Regarding current trading prices, DPAT is priced at $0.02, while JNHMF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas JNHMF's P/E ratio is -0.06. In terms of profitability, DPAT's ROE is +0.45%, compared to JNHMF's ROE of +0.81%. Regarding short-term risk, DPAT is more volatile compared to JNHMF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check JNHMF's competition here
DPAT vs FCHS Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, FCHS has a market cap of 296.6K. Regarding current trading prices, DPAT is priced at $0.02, while FCHS trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas FCHS's P/E ratio is -0.07. In terms of profitability, DPAT's ROE is +0.45%, compared to FCHS's ROE of +0.12%. Regarding short-term risk, DPAT is more volatile compared to FCHS. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check FCHS's competition here
DPAT vs BNYN Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, BNYN has a market cap of 286K. Regarding current trading prices, DPAT is priced at $0.02, while BNYN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas BNYN's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to BNYN's ROE of -14.10%. Regarding short-term risk, DPAT is more volatile compared to BNYN. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check BNYN's competition here
DPAT vs SETO Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, SETO has a market cap of 276.9K. Regarding current trading prices, DPAT is priced at $0.02, while SETO trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas SETO's P/E ratio is -2.22. In terms of profitability, DPAT's ROE is +0.45%, compared to SETO's ROE of +0.00%. Regarding short-term risk, DPAT is more volatile compared to SETO. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check SETO's competition here
DPAT vs KJFI Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, KJFI has a market cap of 220.6K. Regarding current trading prices, DPAT is priced at $0.02, while KJFI trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas KJFI's P/E ratio is -0.06. In terms of profitability, DPAT's ROE is +0.45%, compared to KJFI's ROE of +0.00%. Regarding short-term risk, DPAT is less volatile compared to KJFI. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check KJFI's competition here
DPAT vs CLRD Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, CLRD has a market cap of 140.7K. Regarding current trading prices, DPAT is priced at $0.02, while CLRD trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas CLRD's P/E ratio is -0.01. In terms of profitability, DPAT's ROE is +0.45%, compared to CLRD's ROE of +0.38%. Regarding short-term risk, DPAT is more volatile compared to CLRD. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check CLRD's competition here
DPAT vs TPIA Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, TPIA has a market cap of 113.8K. Regarding current trading prices, DPAT is priced at $0.02, while TPIA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas TPIA's P/E ratio is -0.15. In terms of profitability, DPAT's ROE is +0.45%, compared to TPIA's ROE of +0.60%. Regarding short-term risk, DPAT is less volatile compared to TPIA. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check TPIA's competition here
DPAT vs AMBD Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, AMBD has a market cap of 85.6K. Regarding current trading prices, DPAT is priced at $0.02, while AMBD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas AMBD's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to AMBD's ROE of +1.11%. Regarding short-term risk, DPAT is more volatile compared to AMBD. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check AMBD's competition here
DPAT vs NMHLY Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, NMHLY has a market cap of 41.7K. Regarding current trading prices, DPAT is priced at $0.02, while NMHLY trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas NMHLY's P/E ratio is 0.02. In terms of profitability, DPAT's ROE is +0.45%, compared to NMHLY's ROE of N/A. Regarding short-term risk, DPAT is more volatile compared to NMHLY. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check NMHLY's competition here
DPAT vs DRWN Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, DRWN has a market cap of 24K. Regarding current trading prices, DPAT is priced at $0.02, while DRWN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas DRWN's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to DRWN's ROE of -0.01%. Regarding short-term risk, DPAT is less volatile compared to DRWN. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check DRWN's competition here
DPAT vs HSMD Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, HSMD has a market cap of 19.2K. Regarding current trading prices, DPAT is priced at $0.02, while HSMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas HSMD's P/E ratio is -0.01. In terms of profitability, DPAT's ROE is +0.45%, compared to HSMD's ROE of -0.04%. Regarding short-term risk, DPAT is more volatile compared to HSMD. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check HSMD's competition here
DPAT vs SCAL Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, SCAL has a market cap of 17.4K. Regarding current trading prices, DPAT is priced at $0.02, while SCAL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas SCAL's P/E ratio is 0.04. In terms of profitability, DPAT's ROE is +0.45%, compared to SCAL's ROE of +0.07%. Regarding short-term risk, DPAT is more volatile compared to SCAL. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check SCAL's competition here
DPAT vs GENN Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, GENN has a market cap of 12.1K. Regarding current trading prices, DPAT is priced at $0.02, while GENN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas GENN's P/E ratio is -0.01. In terms of profitability, DPAT's ROE is +0.45%, compared to GENN's ROE of +0.00%. Regarding short-term risk, DPAT is less volatile compared to GENN. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check GENN's competition here
DPAT vs CHCR Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, CHCR has a market cap of 12K. Regarding current trading prices, DPAT is priced at $0.02, while CHCR trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas CHCR's P/E ratio is -0.00. In terms of profitability, DPAT's ROE is +0.45%, compared to CHCR's ROE of N/A. Regarding short-term risk, DPAT is more volatile compared to CHCR. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check CHCR's competition here
DPAT vs ACGI Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, ACGI has a market cap of 10.5K. Regarding current trading prices, DPAT is priced at $0.02, while ACGI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas ACGI's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to ACGI's ROE of +1.11%. Regarding short-term risk, DPAT is less volatile compared to ACGI. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check ACGI's competition here
DPAT vs CEVE Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, CEVE has a market cap of 7.7K. Regarding current trading prices, DPAT is priced at $0.02, while CEVE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas CEVE's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to CEVE's ROE of +2.26%. Regarding short-term risk, DPAT is more volatile compared to CEVE. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check CEVE's competition here
DPAT vs NAFS Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, NAFS has a market cap of 7K. Regarding current trading prices, DPAT is priced at $0.02, while NAFS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas NAFS's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to NAFS's ROE of +1.02%. Regarding short-term risk, DPAT is more volatile compared to NAFS. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check NAFS's competition here
DPAT vs NRTSF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, NRTSF has a market cap of 7K. Regarding current trading prices, DPAT is priced at $0.02, while NRTSF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas NRTSF's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to NRTSF's ROE of +0.00%. Regarding short-term risk, DPAT is less volatile compared to NRTSF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check NRTSF's competition here
DPAT vs PRMD Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, PRMD has a market cap of 5.6K. Regarding current trading prices, DPAT is priced at $0.02, while PRMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas PRMD's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to PRMD's ROE of +0.73%. Regarding short-term risk, DPAT is less volatile compared to PRMD. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check PRMD's competition here
DPAT vs MSGP Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, MSGP has a market cap of 5.2K. Regarding current trading prices, DPAT is priced at $0.02, while MSGP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas MSGP's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to MSGP's ROE of +0.27%. Regarding short-term risk, DPAT is more volatile compared to MSGP. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check MSGP's competition here
DPAT vs SLHPF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, SLHPF has a market cap of 3.9K. Regarding current trading prices, DPAT is priced at $0.02, while SLHPF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas SLHPF's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to SLHPF's ROE of +0.00%. Regarding short-term risk, DPAT is more volatile compared to SLHPF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check SLHPF's competition here
DPAT vs WEQL Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, WEQL has a market cap of 3.5K. Regarding current trading prices, DPAT is priced at $0.02, while WEQL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas WEQL's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to WEQL's ROE of +0.21%. Regarding short-term risk, DPAT is more volatile compared to WEQL. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check WEQL's competition here
DPAT vs BBAL Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, BBAL has a market cap of 3.4K. Regarding current trading prices, DPAT is priced at $0.02, while BBAL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas BBAL's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to BBAL's ROE of +0.45%. Regarding short-term risk, DPAT is more volatile compared to BBAL. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check BBAL's competition here
DPAT vs PAOG Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, PAOG has a market cap of 2.5K. Regarding current trading prices, DPAT is priced at $0.02, while PAOG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas PAOG's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to PAOG's ROE of +0.08%. Regarding short-term risk, DPAT is more volatile compared to PAOG. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check PAOG's competition here
DPAT vs NMMCF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, NMMCF has a market cap of 2.1K. Regarding current trading prices, DPAT is priced at $0.02, while NMMCF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas NMMCF's P/E ratio is 0.00. In terms of profitability, DPAT's ROE is +0.45%, compared to NMMCF's ROE of +0.00%. Regarding short-term risk, DPAT is less volatile compared to NMMCF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check NMMCF's competition here
DPAT vs PPRG Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, PPRG has a market cap of 1.6K. Regarding current trading prices, DPAT is priced at $0.02, while PPRG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas PPRG's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to PPRG's ROE of -0.58%. Regarding short-term risk, DPAT is more volatile compared to PPRG. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check PPRG's competition here
DPAT vs OHAQ Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, OHAQ has a market cap of 1.4K. Regarding current trading prices, DPAT is priced at $0.02, while OHAQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas OHAQ's P/E ratio is 0.01. In terms of profitability, DPAT's ROE is +0.45%, compared to OHAQ's ROE of +0.09%. Regarding short-term risk, DPAT is more volatile compared to OHAQ. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check OHAQ's competition here
DPAT vs BNKL Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, BNKL has a market cap of 1.2K. Regarding current trading prices, DPAT is priced at $0.02, while BNKL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas BNKL's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to BNKL's ROE of -7.69%. Regarding short-term risk, DPAT is more volatile compared to BNKL. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check BNKL's competition here
DPAT vs MAHN Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, MAHN has a market cap of 1.2K. Regarding current trading prices, DPAT is priced at $0.02, while MAHN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas MAHN's P/E ratio is 0.05. In terms of profitability, DPAT's ROE is +0.45%, compared to MAHN's ROE of N/A. Regarding short-term risk, DPAT is more volatile compared to MAHN. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check MAHN's competition here
DPAT vs SLHGF Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, SLHGF has a market cap of 398. Regarding current trading prices, DPAT is priced at $0.02, while SLHGF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas SLHGF's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to SLHGF's ROE of +0.00%. Regarding short-term risk, DPAT is more volatile compared to SLHGF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check SLHGF's competition here
DPAT vs LHRP Comparison July 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 361.2K. In comparison, LHRP has a market cap of 340. Regarding current trading prices, DPAT is priced at $0.02, while LHRP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.50, whereas LHRP's P/E ratio is 0.00. In terms of profitability, DPAT's ROE is +0.45%, compared to LHRP's ROE of N/A. Regarding short-term risk, DPAT is more volatile compared to LHRP. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check LHRP's competition here